President, Chief Executive Officer, & Director
CurrentGenprex (NASDAQ::GNPX) is a clinical-stage biopharmaceutical company focused on the development of novel gene therapies for patients with cancer and diabetes who have limited treatment options. The Company works with world-class research institutions to identify and advance emerging and disruptive therapies.Genprex’s oncology program utilizes a unique, proprietary, non-viral nanoparticle delivery system, called "Oncoprex", to deliver cancer fighting genes back into the human body. Oncoprex is first systemic gene therapy delivery platform used for cancer in humans. Genprex's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for lung cancer (NSCLC and SCLC). The FDA has granted three Fast Track Designations and an Orphan Drug Designation for REQORSA for lung cancer patients in combination with approved therapies from AstraZeneca, Merck and Genentech. Genprex’s diabetes program utilizes a novel infusion process to deliver genes locally to the pancreas through a traditional ERCP via AAV delivery to convert alpha cells into beta-like cells via transdifferentiation. These beta-like cells are able to produce insulin and are distinct enough from beta cells to evade the typical immune response associated with T1D. Our preclinical programs have shown statistically significant results in the creation of new beta cell mass and insulin production and sustained glucose stabilization over durable periods in humanized mice, human islet cells, and non-human primates subjects. For more information, please visit www.genprex.com.